WARNING: “Buffett Indicator” flashing for first time in 50 years

Warren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.

Take these 4 steps today to protect your retirement NOW

Jared Gollob Biography and Net Worth

Insider of Kymera Therapeutics

Jared Gollob is Chief Medical Officer at Kymera Therapeutics. Dr. Gollob is formerly Vice President of Clinical Development and Global Vice President of Medical Affairs at Alnylam Pharmaceuticals.

At Alnylam, Dr. Gollob led early and late stage clinical programs in infectious disease, oncology, and amyloidosis, which resulted in the first proof of concept for RNA interference therapeutics in humans, and culminated in the FDA and EMA approvals of ONPATTRO™ for the treatment of hereditary transthyretin amyloidosis. Prior to joining Alnylam, Dr. Gollob held academic positions at Harvard Medical School and Duke University School of Medicine, and was on staff at Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center and Duke University Medical Center, where he was engaged in both clinical and laboratory research in oncology and immunology. Dr. Gollob has authored more than 50 peer-reviewed papers published in top-tier medical and scientific journals. He received his BA and MD from Columbia University, and completed clinical training in internal medicine and medical oncology at Massachusetts General Hospital and the Dana-Farber Cancer Institute, respectively.

What is Jared Gollob's net worth?: The estimated net worth of Jared Gollob is at least $3.88 million as of July 16th, 2024. Dr. Gollob owns 95,470 shares of Kymera Therapeutics stock worth more than $3,881,810 as of December 21st. This net worth approximation does not reflect any other investments that Dr. Gollob may own. Additionally, Dr. Gollob receives a salary of $723,600.00 as Insider at Kymera Therapeutics. Learn More about Jared Gollob's net worth.
How old is Jared Gollob?: Dr. Gollob is currently 59 years old. There are 4 older executives and no younger executives at Kymera Therapeutics. The oldest executive at Kymera Therapeutics is Ms. Ellen V. Chiniara Esq., J.D., Chief Legal Officer & Corporate Secretary, who is 65 years old. Learn More on Jared Gollob's age.
What is Jared Gollob's salary?: As the Insider of Kymera Therapeutics, Inc., Dr. Gollob earns $723,600.00 per year. There are 2 executives that earn more than Dr. Gollob. The highest earning executive at Kymera Therapeutics is Dr. Nello Mainolfi M.D., Ph.D., Co-Founder, President, CEO & Director, who commands a salary of $1,080,000.00 per year. Learn More on Jared Gollob's salary.
How do I contact Jared Gollob?: The corporate mailing address for Dr. Gollob and other Kymera Therapeutics executives is 200 Arsenal Yards Blvd. Suite 230, Watertown MA, 02472. Kymera Therapeutics can also be reached via phone at 857-285-5300 and via email at [email protected]. Learn More on Jared Gollob's contact information.
Has Jared Gollob been buying or selling shares of Kymera Therapeutics?: Jared Gollob has not been actively trading shares of Kymera Therapeutics in the last ninety days. Most recently, Jared Gollob sold 23,145 shares of the business's stock in a transaction on Tuesday, July 16th. The shares were sold at an average price of $45.81, for a transaction totalling $1,060,272.45. Following the completion of the sale, the insider now directly owns 95,470 shares of the company's stock, valued at $4,373,480.70. Learn More on Jared Gollob's trading history.
Who are Kymera Therapeutics' active insiders?: Kymera Therapeutics' insider roster includes Jeffrey Albers (Director), Bruce Booth (Director), Richard Chesworth (Insider), Ellen Chiniara (Chief Legal Officer and Corporate Secretary), Jared Gollob (Insider), Bruce Jacobs (CFO), and Nello Mainolfi (CEO). Learn More on Kymera Therapeutics' active insiders.
Are insiders buying or selling shares of Kymera Therapeutics?: In the last twelve months, insiders at the sold shares 16 times. They sold a total of 1,008,191 shares worth more than $40,176,324.03. The most recent insider tranaction occured on September, 17th when Director Pamela Esposito sold 13,500 shares worth more than $651,780.00. Insiders at Kymera Therapeutics own 15.8% of the company. Learn More about insider trades at Kymera Therapeutics.
Information on this page was last updated on 9/17/2024.

Jared Gollob Insider Trading History at Kymera Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/16/2024	Sell	23,145	$45.81	$1,060,272.45	95,470
2/9/2024	Sell	46,137	$35.50	$1,637,863.50	74,709
11/2/2021	Sell	14,996	$63.22	$948,047.12
3/15/2021	Sell	10,305	$60.17	$620,051.85	49,747
3/11/2021	Sell	4,695	$60.05	$281,934.75	49,747
2/19/2021	Sell	8,887	$55.09	$489,584.83	99,997
2/17/2021	Sell	7,550	$58.39	$440,844.50	99,997

Jared Gollob Buying and Selling Activity at Kymera Therapeutics

Kymera Therapeutics Company Overview

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Today's Range

Now: $40.66

$38.24

$40.78

50 Day Range

MA: $46.00

$39.06

$51.84

2 Week Range

Now: $40.66

$22.35

$53.27

Volume

1,145,939 shs

Average Volume

582,401 shs

Market Capitalization

$2.63 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.16

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minutes of stepping into the Oval Office...

I put all the details together for you here — but please hurry.

Jared Gollob Biography and Net Worth

What is Jared Gollob's net worth?

How old is Jared Gollob?

What is Jared Gollob's salary?

How do I contact Jared Gollob?

Has Jared Gollob been buying or selling shares of Kymera Therapeutics?

Who are Kymera Therapeutics' active insiders?

Are insiders buying or selling shares of Kymera Therapeutics?